Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept
Authors:
- William D TutroneWTWilliam D Tutrone
- Jeffrey M WeinbergJWJeffrey M Weinberg
- 1 April 2006
- journal article
- Published by Taylor & Francis in Expert Review of Dermatology
- Vol. 1 (2) , 207-216
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialThe Lancet, 2005
- A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBritish Journal of Dermatology, 2005
- Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 casesJournal of the American Academy of Dermatology, 2004
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasisClinical Therapeutics, 2003
- Infection complications associated with the use of biologic agentsRheumatic Disease Clinics of North America, 2003
- New Developments in the Treatment of PsoriasisArchives of Dermatology, 2002
- Biologic Therapy for PsoriasisArchives of Dermatology, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001